secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018791
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024
--------------------------------------------------------------------------------

- Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.
- Cash and investments $9.8M; believes funding sufficient through end of 2024.
- Stacy Lindborg appointed President and CEO effective May 13, 2024; previously a director and Co-CEO of BrainStorm.
- OVATION 2 Study of IMNN-001 in advanced ovarian cancer: interim PFS delay ~3 months, OS improvement ~9 months; final readout mid-2024.
- FDA cleared IND for IMNN-101 seasonal COVID booster; Phase 1 starting Q2 2024. Received $1.3M non-dilutive from NJ NOL sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/0001493152-24-018791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315224018791/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer